Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H10FNO3 |
| Molecular Weight | 271.2432 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC2=C(OC(=N2)C3=CC=C(O)C(F)=C3)C(C=C)=C1
InChI
InChIKey=MQIMZDXIAHJKQP-UHFFFAOYSA-N
InChI=1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,18-19H,1H2
| Molecular Formula | C15H10FNO3 |
| Molecular Weight | 271.2432 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Prinaberel is a selective agonist of estrogen receptor beta. Although initially developed for the treatment of endometriosis, the drug was also shown to be effective in vitro in other inflammatory diseases. Phase II clinical studied revealed its effectiveness in case of Crohn's disease and endometriosis, but the drug failed to demonstrate antiinflammatory efficacy in RA patients.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15456246
Curator's Comment: # Wyeth Research
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14500559 |
5.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive [IC50 26.837 uM] | ||||
| yes [IC50 21.3174 uM] | ||||
| yes [IC50 6.7412 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Selectivity of natural, synthetic and environmental estrogens for zebrafish estrogen receptors. | 2014-10-01 |
|
| Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006-11 |
|
| Evaluation of an estrogen receptor-beta agonist in animal models of human disease. | 2003-10 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20556817
In phase II patients received 5, 25, or 75 mg of prinaberel for 12 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18097065
Human U2OS osteosarcoma cell lines stably expressing a tetracycline regulated ERalpha or beta were treated with 1 ug/ml doxycycline to induce ER expression and then with increasing concentrations of prinaberel (10(-6)-10(-11) M) to test drug effect on proinflammatory genes.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:14:24 GMT 2025
by
admin
on
Mon Mar 31 18:14:24 GMT 2025
|
| Record UNII |
A9C8MNF7CA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1821
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8771
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
DB06832
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
300000034321
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
524684-52-4
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
DTXSID301030354
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
Prinaberel
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
656954
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
QQ-08
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
A9C8MNF7CA
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
C76959
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL450940
Created by
admin on Mon Mar 31 18:14:24 GMT 2025 , Edited by admin on Mon Mar 31 18:14:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
200 FOLD SELECTIVITY OVER ALPHA RECEPTOR
AGONIST
IC50
|
||
|
BINDER->LIGAND |
BINDING
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |